Retinoids have significant antiproliferative effect against in patients with Ph-positive CML, we conducted a pilot study chronic myelogenous leukemia (CML) cells in vitro. We conwith ATRA in patients with CML resistant to IFN-␣ therapy. 
Therapy
All-trans retinoic acid was given as 175 mg/m 2 daily divided Introduction in two doses regardless of fasting status and continued until evidence of disease progression or toxicity. This dose was Retinoids play an important role in the regulation of normal selected based on phase I trials in solid tumors where doses hematopoiesis.
1 9-cis-retinoic acid and all-trans retinoic acid as high as 200 mg/m 2 were used. 14 A bone marrow aspirate (ATRA) can stimulate the growth of normal CFU-GM, 2, 3 and complete blood counts were performed prior to the start whereas both stimulation 2, 3 and inhibition 4, 5 of BFU-E have of therapy. Peripheral blood counts were monitored 1-2 been reported. The effect is more significant on day 14 CFUtimes/week for 2 months, and then every 2 to 4 weeks. GM colonies compared to day 7 colonies, suggesting it is Patients with grade 3 or 4 toxicity had their dose reduced to restricted to relatively immature myeloid cells. 6, 7 In contrast, 90 mg/m 2 . If toxicity persisted, the patient was taken off the retinoids inhibit the clonal growth of acute myeloid leukemia study. cell lines and fresh acute myeloid leukemia cell lines, 2, 8 without inducing their differentiation. 2 In chronic myelogenous leukemia (CML), retinoids significantly inhibit the growth and recloning capacity of colonies and clusters of CFU-GM cul-
Response criteria
tured in vitro. 7, 9 In juvenile CML, treatment with isotretinoin can induce
Patients were considered to have antileukemia effect if there some durable remissions. 10 Retinoids have only been investiwas at least a 25% decrease in the WBC count for a minimum gated in isolated cases of Philadelphia chromosome (Ph)-chroof 3 months for patients in chronic phase, or improvement in mosome positive CML, in particular in promyelocytic blastic accelerated phase features or decrease in blasts by at least phase.
11 A study by Meyskens et al 12 suggested that in chronic 25% for patients in accelerated and blastic phase, respectphase CML the addition of vitamin A to therapy with busulfan ively. A complete hematologic remission was defined as a resulted in a prolonged survival and progression-free surnormalization of the bone marrow, with Ͻ5% blasts, and of vival.
12 peripheral blood with WBC less than 10 × 10 9 /l, and no blasts, To determine the effect of retinoids as single agent therapy promyelocytes, or myelocytes in the peripheral blood, together with disappearance of all signs and symptoms of the disease. A partial response was defined as normalization of Results the disease progressed while on therapy. The patient was taken off study after 23 days of treatment.
A total of 13 patients with Ph-positive CML were included and their clinical characteristics are described in Table 1 . Seven Toxicity patients (54%) were in late chronic phase, five (38%) in accelerated phase, and one (8%) in blastic phase. Their median age Therapy was well tolerated. The most common side-effects included headache in seven patients (54%), which was severe was 52 years (range 16 to 75); six were females. Performance status was 1 in all cases. All patients had been previously in three (23%); one patient required a 50% dose reduction following which symptoms resolved. Four patients (31%) had treated: two (15%) had received only one prior therapy regimen, seven (54%) had received two regimens, and four (31%) nausea, which was severe in one patient; three patients (23%) had dry skin, and three (23%) had dry mucosal membranes. had received more than two prior regimens. All but one patient (in late chronic phase) had received and were refracThere were no documented elevations of liver function tests or triglycerides. tory to prior therapy with interferon-␣. The median duration of therapy was 56 days (range 11 to 190).
There was no evidence of antileukemic effect among patients in late chronic phase. In one patient (patient 7) there Discussion was a significant decrease in the WBC count. This patient had an initial WBC count of 41 × 10 9 /l at the start of therapy, and The results from this pilot study suggest that, in this population of patients with extensively treated, advanced phase, Ph-posiby day 22 it had decreased to 14.6 × 10 9 /l. However, the response was rapidly lost, and by day 48 the WBC count was tive CML, ATRA is not effective as single agent therapy. These results contrast with another retinoid, 13-cis retinoic acid, in 53 × 10 9 /l. In all other patients in late chronic phase, WBC counts either remained around baseline levels with minor patients with juvenile CML. 10 Castleberry et al 10 treated 10 patients with juvenile CML with 13-cis retinoic acid and fluctuations (one patient), or showed a steady increase (five patients), sometimes very rapidly requiring discontinuation of observed a complete plus partial response rate of 50% with a median duration of response of 37 months. 10 The clinical therapy. In no case was there progression to accelerated or blastic phase while receiving ATRA therapy.
experience in adult CML is very limited. Arlin et al 15 used 13-cis retinoic acid after chemotherapy with cytarabine, daunoruAmong patients with accelerated phase, none met the criteria for complete or partial hematologic response. However, bicin, and 6-thioguanine in 17 evaluable patients with early chronic phase Ph-positive CML. One patient achieved a comin some cases, there was an improvement in the features of accelerated phase, although the improvement was usually plete cytogenetic remission and seven patients had partial cytogenetic responses. The median remission duration was transient and lasted less than 3 months in all cases. One patient (patient 11) had a promyelocytic transformation of the 1.6 months. These results did not differ from their previous experience with similar chemotherapy without retinoids. 15 In disease, with 51% promyelocytes in the bone marrow and 37% in peripheral blood, with a WBC count of 40.3 × 10 9 /l contrast, in a randomized trial from the Southwest Oncology Group, patients with previously untreated early chronic phase and a platelet count of 35 × 10 9 /l. There was no evidence of a translocation t(15;17). After 2 weeks of therapy, the promywere randomized to receive busulfan alone or in combination with vitamin A. 12 After adjusting for prognostic variables, a elocyte count in the bone marrow decreased to 28% and in peripheral blood to 6%. However, the WBC count increased significantly prolonged survival and progression-free survival were observed among patients who received vitamin A. 12 to 77.1 × 10 9 /l and the platelet count was unchanged. The patient was lost to follow-up. Another patient (patient 8) was ATRA has been used in patients with chronic myelomonocytic leukemia with only some minor responses, 16 but rarely in in accelerated phase based on a bone marrow blast count of 16% and promyelocyte count of 20%, thrombocytopenia CML. Wiernik et al 11 treated a patient with a promyelocytic blastic phase of CML with single agent ATRA and obtained a (75 × 10 9 /l) and peripheral blood blasts of 18% and basophils of 30%. She had a transient improvement with the bone marpartial remission lasting almost 3 months.
11
In vitro studies have documented significant inhibition of row blast count decreasing to 10% and the promyelocyte count to 8.5%; the peripheral blood blasts decreased to 1% proliferation of CFU-GM from patients with CML with retinoids. 7,9 Although our results do not support a clinical benefit and the basophils to 15%, while the platelet count recovered to 140 × 10 9 /l by day 39 of therapy. However, this response from these experimental observations, several considerations should be made. First, CFU-GM from patients with accelerwas transient and the disease later progressed. The patient was taken off study by day 74 of therapy. A third patient (patient ated or blastic phase CML are inhibited approximately 1000-fold more efficiently than those from patients in chronic 10) had an initial blast count of 15% in the bone marrow and 13% in peripheral blood, with WBC counts of 25 × 10 9 /l. phase. 17, 18 In this regard, it is interesting to note that although no clear responses were seen among our seven patients in late There was a decrease on blast count both in the bone marrow (6%) and peripheral blood (3%), although the WBC count did chronic phase, some improvement was seen in some patients in accelerated phase, including a decrease in blast, basophil, not change. The response was eventually lost and the patient taken off study on day 124 of therapy when the peripheral and/or promyelocytes in the blood and bone marrow. However, the effect was transient and in all cases patients had to blast count had increased to 21%. The fourth patient (patient 12) had a stable disease for 6 months while on therapy, with stop therapy due to disease progression. Second, high concentrations of ATRA, in the range of 10 −6 M are required to inhibit a decrease in bone marrow basophils from 34 to 8.3%, but eventually transformed to blastic phase and was taken off therby 50% the growth of CFU-GM in vitro. 2, 7, 17, 18 It has been shown that with continuous treatment with oral ATRA, there apy. The fifth patient (patient 9), with clonal evolution (trisomy 8), had no significant hematologic response; clonal evolution is a progressive reduction of plasma concentrations of the drug. 19 Interestingly, in patients with acute promyelocytic leupersisted while on therapy.
One patient (patient 13) in blastic phase was included and kemia who develop clinical resistance and decreased plasma HHT, homoharringtonine; XRT, radiotherapy; BMT, autologous bone marrow transplantation; PB, peripheral blood; BM, bone marrow.
